S&P 500   3,375.58 (+0.06%)
DOW   27,937.78 (+0.15%)
QQQ   271.97 (-0.19%)
AAPL   457.28 (-0.60%)
MSFT   208.54 (-0.08%)
FB   259.55 (-0.67%)
GOOGL   1,510.84 (-0.38%)
AMZN   3,145.17 (-0.50%)
NVDA   459.86 (+0.47%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.81 (-0.72%)
AMD   81.58 (-0.32%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,375.58 (+0.06%)
DOW   27,937.78 (+0.15%)
QQQ   271.97 (-0.19%)
AAPL   457.28 (-0.60%)
MSFT   208.54 (-0.08%)
FB   259.55 (-0.67%)
GOOGL   1,510.84 (-0.38%)
AMZN   3,145.17 (-0.50%)
NVDA   459.86 (+0.47%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.81 (-0.72%)
AMD   81.58 (-0.32%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,375.58 (+0.06%)
DOW   27,937.78 (+0.15%)
QQQ   271.97 (-0.19%)
AAPL   457.28 (-0.60%)
MSFT   208.54 (-0.08%)
FB   259.55 (-0.67%)
GOOGL   1,510.84 (-0.38%)
AMZN   3,145.17 (-0.50%)
NVDA   459.86 (+0.47%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.81 (-0.72%)
AMD   81.58 (-0.32%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
S&P 500   3,375.58 (+0.06%)
DOW   27,937.78 (+0.15%)
QQQ   271.97 (-0.19%)
AAPL   457.28 (-0.60%)
MSFT   208.54 (-0.08%)
FB   259.55 (-0.67%)
GOOGL   1,510.84 (-0.38%)
AMZN   3,145.17 (-0.50%)
NVDA   459.86 (+0.47%)
CGC   17.18 (-0.81%)
BABA   252.56 (-0.46%)
TSLA   1,647.40 (+1.63%)
GE   6.68 (+1.21%)
MU   45.81 (-0.72%)
AMD   81.58 (-0.32%)
T   30.13 (+0.74%)
F   7.09 (+0.85%)
ACB   10.58 (+3.93%)
GILD   68.43 (+0.37%)
NFLX   482.61 (+0.27%)
DIS   130.70 (-0.20%)
BAC   26.52 (+0.65%)
BA   178.15 (+1.96%)
Log in

NYSEAMERICAN:ARMPArmata Pharmaceuticals Stock Price, Forecast & News

$3.44
+0.10 (+2.99 %)
(As of 08/14/2020 12:36 PM ET)
Add
Compare
Today's Range
$3.44
Now: $3.44
$3.50
50-Day Range N/A
52-Week Range
$2.52
Now: $3.44
$6.92
Volume200 shs
Average Volume98,654 shs
Market Capitalization$37.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
Current SymbolNYSEAMERICAN:ARMP
CUSIPN/A
CIKN/A
WebN/A
Phone(310) 655-2928

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$37.59 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$3.44
+0.10 (+2.99 %)
(As of 08/14/2020 12:36 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Armata Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Armata Pharmaceuticals
.

When is Armata Pharmaceuticals' next earnings date?

Armata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Armata Pharmaceuticals
.

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) released its quarterly earnings results on Thursday, August, 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.06.
View Armata Pharmaceuticals' earnings history
.

What price target have analysts set for ARMP?

3 equities research analysts have issued 12-month price objectives for Armata Pharmaceuticals' shares. Their forecasts range from $5.00 to $9.00. On average, they expect Armata Pharmaceuticals' share price to reach $7.33 in the next year. This suggests a possible upside of 122.2% from the stock's current price.
View analysts' price targets for Armata Pharmaceuticals
.

What are Wall Street analysts saying about Armata Pharmaceuticals stock?

Here are some recent quotes from research analysts about Armata Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. " (7/31/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy and $7 price target. The sole contributor to our valuation, at this point is AB-SA01, with a projected 15% chance of success with $415 million in peak sales off of a 2024 launch. Overall, we believe that our projected chance of success could be considered conservative based on the efficacy and safety profile, to date, in very sick patients, and continues to highlight the valuation disconnect, in our belief. We do not include projections for the P. aeruginosa program, and would look to reevaluate based on visibility on the path forward." (8/15/2019)

Has Armata Pharmaceuticals been receiving favorable news coverage?

Headlines about ARMP stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Armata Pharmaceuticals earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Armata Pharmaceuticals
.

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a increase in short interest in June. As of June 30th, there was short interest totaling 58,900 shares, an increase of 90.0% from the June 15th total of 31,000 shares. Based on an average daily volume of 21,000 shares, the short-interest ratio is presently 2.8 days.
View Armata Pharmaceuticals' Short Interest
.

Who are some of Armata Pharmaceuticals' key competitors?

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Altimmune (ALT), Crispr Therapeutics (CRSP), Pfizer (PFE), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), Aduro BioTech (ADRO) and Micron Technology (MU).

Who are Armata Pharmaceuticals' key executives?

Armata Pharmaceuticals' management team includes the following people:
  • Todd R. Patrick, Chief Executive Officer & Director
  • Brian C. Varnum, President & Chief Development Officer
  • Duane A. Morris, Vice President-Operations
  • Steven Robert Martin, Chief Financial Officer & Head-Media Contacts

What is Armata Pharmaceuticals' stock symbol?

Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP."

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Armata Pharmaceuticals' stock price today?

One share of ARMP stock can currently be purchased for approximately $3.30.

How big of a company is Armata Pharmaceuticals?

Armata Pharmaceuticals has a market capitalization of $36.06 million.

How can I contact Armata Pharmaceuticals?

The company can be reached via phone at (310) 655-2928.

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.